212 related articles for article (PubMed ID: 31373873)
1. Role of Cytokines in Ranibizumab Therapy for Macular Edema in Patients with Central Retinal Vein Occlusion.
Matsushima R; Noma H; Yasuda K; Goto H; Shimura M
J Ocul Pharmacol Ther; 2019 Sep; 35(7):407-412. PubMed ID: 31373873
[No Abstract] [Full Text] [Related]
2. Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema.
Noma H; Yasuda K; Shimura M
Eur J Ophthalmol; 2021 Jan; 31(1):204-210. PubMed ID: 31690095
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Effect of Intravitreal Conbercept and Ranibizumab on Aqueous Humor Cytokines in Central Retinal Vein Occlusion-Related Macular Edema.
Cui W; Sun XY; Sun LP; Li J; Liu ZL; Zhang H
J Ocul Pharmacol Ther; 2021; 37(1):52-59. PubMed ID: 33216685
[No Abstract] [Full Text] [Related]
4. POSSIBLE MOLECULAR BASIS OF BEVACIZUMAB THERAPY FOR MACULAR EDEMA IN BRANCH RETINAL VEIN OCCLUSION.
Noma H; Mimura T; Yasuda K; Shimura M
Retina; 2016 Sep; 36(9):1718-25. PubMed ID: 26866529
[TBL] [Abstract][Full Text] [Related]
5. Cytokine Kinetics after Monthly Intravitreal Bevacizumab for Retinal Vein Occlusion Associated with Macular Oedema.
Noma H; Mimura T; Yasuda K; Shimura M
Ophthalmic Res; 2016; 56(4):207-214. PubMed ID: 27160159
[TBL] [Abstract][Full Text] [Related]
6. Functional-morphological parameters, aqueous flare and cytokines in macular oedema with branch retinal vein occlusion after ranibizumab.
Noma H; Mimura T; Yasuda K; Shimura M
Br J Ophthalmol; 2017 Feb; 101(2):180-185. PubMed ID: 27073207
[TBL] [Abstract][Full Text] [Related]
7. Cytokines and Recurrence of Macular Edema after Intravitreal Ranibizumab in Patients with Branch Retinal Vein Occlusion.
Noma H; Mimura T; Yasuda K; Nakagawa H; Motohashi R; Kotake O; Shimura M
Ophthalmologica; 2016; 236(4):228-234. PubMed ID: 27832655
[TBL] [Abstract][Full Text] [Related]
8. The correlation between cytokine levels in the aqueous humor and the prognostic value of anti-vascular endothelial growth factor therapy for treating macular edema resulting from retinal vein occlusion.
Yong H; Qi H; Yan H; Wu Q; Zuo L
Graefes Arch Clin Exp Ophthalmol; 2021 Nov; 259(11):3243-3250. PubMed ID: 34059950
[TBL] [Abstract][Full Text] [Related]
9. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
[TBL] [Abstract][Full Text] [Related]
10. Effects of ranibizumab on growth factors and mediators of inflammation in the aqueous humor of patients with diabetic macular edema.
Utsumi T; Noma H; Yasuda K; Goto H; Shimura M
Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2597-2603. PubMed ID: 33772356
[TBL] [Abstract][Full Text] [Related]
11. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
12. Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema.
Yasuda K; Noma H; Mimura T; Nonaka R; Sasaki S; Suganuma N; Shimura M
Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374257
[No Abstract] [Full Text] [Related]
13. Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema.
Noma H; Mimura T; Yasuda K; Shimura M
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1122-8. PubMed ID: 25634982
[TBL] [Abstract][Full Text] [Related]
14. Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
Sohn HJ; Han DH; Lee DY; Nam DH
Acta Ophthalmol; 2014 May; 92(3):e217-24. PubMed ID: 23889803
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal Ranibizumab and Aqueous Humor Factors/Cytokines in Major and Macular Branch Retinal Vein Occlusion.
Noma H; Mimura T; Yasuda K; Nakagawa H; Motohashi R; Kotake O; Shimura M
Ophthalmologica; 2016; 235(4):203-7. PubMed ID: 27003517
[TBL] [Abstract][Full Text] [Related]
16. Six-month changes in cytokine levels after intravitreal bevacizumab injection for diabetic macular oedema and macular oedema due to central retinal vein occlusion.
Wen J; Jiang Y; Zheng X; Zhou Y
Br J Ophthalmol; 2015 Oct; 99(10):1334-40. PubMed ID: 25841235
[TBL] [Abstract][Full Text] [Related]
17. AQUEOUS HUMOR CYTOKINES AND THERAPEUTIC CUSTOMIZATION IN NONRESPONDING MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.
Modi A; Sharma K; Sudhakar NP; Yadav NK
Retin Cases Brief Rep; 2021 Mar; 15(2):127-130. PubMed ID: 30664079
[TBL] [Abstract][Full Text] [Related]
18. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
Hu Q; Li H; Xu W; Du Y; Ma C; He J
Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
[TBL] [Abstract][Full Text] [Related]
19. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Ozkaya A; Tarakcioglu HN; Tanir I
Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF Therapy Reduces Inflammation in Diabetic Macular Edema.
Imazeki M; Noma H; Yasuda K; Motohashi R; Goto H; Shimura M
Ophthalmic Res; 2021; 64(1):43-49. PubMed ID: 32454504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]